These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 26782971)

  • 1. Long-term (52 weeks) safety and tolerability of umeclidinium in Japanese patients with chronic obstructive pulmonary disease.
    Yamagata E; Soutome T; Hashimoto K; Mihara K; Tohda Y
    Curr Med Res Opin; 2016 May; 32(5):967-73. PubMed ID: 26782971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies.
    Siler TM; Kerwin E; Sousa AR; Donald A; Ali R; Church A
    Respir Med; 2015 Sep; 109(9):1155-63. PubMed ID: 26117292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 28-Day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trial.
    Feldman G; Walker RR; Brooks J; Mehta R; Crater G
    Pulm Pharmacol Ther; 2012 Dec; 25(6):465-71. PubMed ID: 22955035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials.
    Decramer M; Anzueto A; Kerwin E; Kaelin T; Richard N; Crater G; Tabberer M; Harris S; Church A
    Lancet Respir Med; 2014 Jun; 2(6):472-86. PubMed ID: 24835833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Systematic Review of the Efficacy and Safety of a Fixed-Dose Combination of Umeclidinium and Vilanterol for the Treatment of COPD.
    Rodrigo GJ; Neffen H
    Chest; 2015 Aug; 148(2):397-407. PubMed ID: 25798635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of verapamil on systemic exposure and safety of umeclidinium and vilanterol: a randomized and open-label study.
    Mehta R; Kelleher D; Preece A; Hughes S; Crater G
    Int J Chron Obstruct Pulmon Dis; 2013; 8():159-67. PubMed ID: 23569370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD.
    Donohue JF; Maleki-Yazdi MR; Kilbride S; Mehta R; Kalberg C; Church A
    Respir Med; 2013 Oct; 107(10):1538-46. PubMed ID: 23830094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual Bronchodilation with Indacaterol Maleate/Glycopyrronium Bromide Compared with Umeclidinium Bromide/Vilanterol in Patients with Moderate-to-Severe COPD: Results from Two Randomized, Controlled, Cross-over Studies.
    Kerwin E; Ferguson GT; Sanjar S; Goodin T; Yadao A; Fogel R; Maitra S; Sen B; Ayers T; Banerji D
    Lung; 2017 Dec; 195(6):739-747. PubMed ID: 28993871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Umeclidinium for treating COPD: an evaluation of pharmacologic properties, safety and clinical use.
    Manickam R; Asija A; Aronow WS
    Expert Opin Drug Saf; 2014 Nov; 13(11):1555-61. PubMed ID: 25294427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Umeclidinium in patients with COPD: a randomised, placebo-controlled study.
    Trivedi R; Richard N; Mehta R; Church A
    Eur Respir J; 2014 Jan; 43(1):72-81. PubMed ID: 23949963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model.
    Wilson MR; Patel JG; Coleman A; McDade CL; Stanford RH; Earnshaw SR
    Int J Chron Obstruct Pulmon Dis; 2017; 12():997-1008. PubMed ID: 28392684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose response of umeclidinium administered once or twice daily in patients with COPD: a pooled analysis of two randomized, double-blind, placebo-controlled studies.
    Donohue JF; Kalberg C; Shah P; Beerahee M; Mehta R; Gunawan R; Church A
    J Clin Pharmacol; 2014 Nov; 54(11):1214-20. PubMed ID: 24895108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects.
    Kelleher D; Tombs L; Preece A; Brealey N; Mehta R
    Pulm Pharmacol Ther; 2014 Oct; 29(1):49-57. PubMed ID: 25020273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of umeclidinium on lung function and symptoms in patients with fixed airflow obstruction and reversibility to salbutamol: A randomised, 3-phase study.
    Lee L; Kerwin E; Collison K; Nelsen L; Wu W; Yang S; Pascoe S
    Respir Med; 2017 Oct; 131():148-157. PubMed ID: 28947022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhaled Umeclidinium in COPD Patients: A Review and Meta-Analysis.
    Pleasants RA; Wang T; Gao J; Tang H; Donohue JF
    Drugs; 2016 Mar; 76(3):343-61. PubMed ID: 26755180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects.
    Feldman GJ; Edin A
    Ther Adv Respir Dis; 2013 Dec; 7(6):311-9. PubMed ID: 24004659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of umeclidinium added to inhaled corticosteroid/long-acting β2-agonist in patients with symptomatic COPD: a randomised, double-blind, parallel-group study.
    Sousa AR; Riley JH; Church A; Zhu CQ; Punekar YS; Fahy WA
    NPJ Prim Care Respir Med; 2016 Jun; 26():16031. PubMed ID: 27334739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Umeclidinium for the treatment of chronic obstructive pulmonary disease.
    Segreti A; Calzetta L; Rogliani P; Cazzola M
    Expert Rev Respir Med; 2014 Dec; 8(6):665-71. PubMed ID: 25312239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Umeclidinium bromide and vilanterol in combination for the treatment of chronic obstructive pulmonary disease.
    Kelly E
    Expert Rev Clin Pharmacol; 2014 Jul; 7(4):403-13. PubMed ID: 24909949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 μg compared with tiotropium 18 μg in patients with COPD.
    Feldman G; Maltais F; Khindri S; Vahdati-Bolouri M; Church A; Fahy WA; Trivedi R
    Int J Chron Obstruct Pulmon Dis; 2016; 11():719-30. PubMed ID: 27103795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.